

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Australian Pharmaceutical Industries Limited</b>
<b>ABN</b>	<b>57 000 004 320</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Richard Craig Vincent
<b>Date of last notice</b>	16 March 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	3 November 2017
<b>No. of securities held prior to change</b>	<p><b>145,444</b> ordinary shares</p> <p><b>297,444</b> performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2014 to 31 August 2017</p> <p><b>44,069</b> performance rights granted under API's Short Term Incentive Plan 2015-2016</p> <p><b>99,180</b> performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2015 to 31 August 2018</p> <p><b>44,877</b> performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2016 to 31 August 2019</p>

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	283,841
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil. Shares issued upon vesting of performance rights under API's Long Term Incentive Plan (2014 – 2017 offer) and vesting of performance rights under API's Short Term Incentive Plan (2015 – 2016 offer)
<b>No. of securities held after change</b>	<p><b>429,285</b> ordinary shares (<b>updated</b>)</p> <p><b>Nil</b>  Performance Rights under the API Long Term Incentive Plan (2014 - 2017) (<b>updated</b> following the vesting of 239,772 Performance Rights into ordinary shares, and the lapsing of 57,672 Performance Rights)</p> <p><b>Nil</b>  Performance Rights under the API Short Term Incentive Plan (2015 – 2016) (<b>updated</b> following the vesting of 44,069 Performance Rights into ordinary shares)</p> <p><b>99,180</b> performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2015 to 31 August 2018 (<b>no change</b>)</p> <p><b>44,877</b> performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2016 to 31 August 2019 (<b>no change</b>)</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Shares issued upon vesting of performance rights under API's Long Term Incentive Plan (2014 – 2017 offer) and API's Short Term Incentive Plan (2015 – 2016 offer)

+ See chapter 19 for defined terms.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	n/a
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.